<DOC>
	<DOCNO>NCT02250976</DOCNO>
	<brief_summary>To develop combination product micronized fenofibrate plus pitavastatin , would like evaluate comparative pharmacokinetics safety fixed-dose combination ( micronized fenofibrate160mg+pitavastatin Ca 2mg ) versus coadministration Lipilfen cap.160mg ( micronized fenofibrate160mg ) Livaro tab . 2mg ( pitavastatin Ca 2mg ) feed condition healthy male volunteer .</brief_summary>
	<brief_title>The Pharmacokinetic Study Fixed-dose Combination Micronized Fenofibrate Pitavastatin Ca</brief_title>
	<detailed_description />
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Healthy male subject age 19 55 screen visit Body weight≥50kg within Ideal body weight±20 % Subject judge eligible accord clinical laboratory test include hematological examination , blood chemistry examination , urine analysis Subject volunteerly determine participate agree comply precaution totally understand detailed explanation study Subject serious active cardiovascular , respiratory , hepatology , renal , hematologic , gastrointestinal , immunologic , dermal , neurologic , psychological disease history disease Subject symptoms acute disease within 28days prior study medication dose Subject know history affect absorption , distribution , metabolism excretion drug Subject clinically significant active chronic disease Subject follow condition laboratory test i. AST ( aspartate aminotransferase ) ALT ( alanine transferase ) &gt; upper normal limit × 1.5 ii . Total bilirubin &gt; upper normal limit × 1.5 iii . renal failure Creatinine clearance &lt; 50mL/min iv . creatine phosphokinase &gt; upper normal limit × 2 Positive test result hepatitis B virus surface antigen , antihepatitis C virus antibody , human immunodeficiency virus antigen/antibody , venereal disease research laboratory test Use prescription medication within 14 day prior study medication dosing Use medication overthecounter medication include oriental medication within 7 day prior study medication dose Subject clinically significant allergic disease ( except mild allergic rhinitis mild allergic dermatitis need administer drug ) Subject know hypersensitivity reaction fenofibrate , fenofibric acid statin gallbladder disease Subject experience photoallergy phototoxicity administrate fibrates ketoprofen Subject genetic deficiency galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption Subject able take institutional standard meal Subject whole blood donation within 60days , component blood donation within 20days Subjects receive blood transfusion within 30days prior study medication dose Participation clinical investigation within 60days prior study medication dose Continued excessive use caffeine ( caffeine &gt; five cups/day ) , alcohol ( alcohol &gt; 30g/day ) severe heavy smoker ( cigarette &gt; 10 cigarette per day ) Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>